---
title: "Novo Nordisk A/S (NVO.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/NVO.US/overview.md"
symbol: "NVO.US"
name: "Novo Nordisk A/S"
parent: "https://longbridge.com/zh-CN/quote/NVO.US.md"
datetime: "2026-04-17T08:47:38.743Z"
locales:
  - [en](https://longbridge.com/en/quote/NVO.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NVO.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NVO.US/overview.md)
---

# Novo Nordisk A/S (NVO.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | 制药 |
| 交易所 | US Market |
| 地址 | Novo Alle 1, Bagsvaerd, Capital Region of Denmark, Denmark |
| 官网 | [www.novonordisk.com](https://www.novonordisk.com) |

## 公司简介

诺和诺德公司（Novo Nordisk A/S）及其子公司从事药品的研究与开发、生产和分销。公司通过两个业务部门运营：肥胖与糖尿病护理以及罕见疾病。肥胖与糖尿病护理部门提供糖尿病、肥胖、心血管及其他新兴治疗领域的产品。罕见疾病部门则提供罕见血液疾病、罕见内分泌疾病和激素替代疗法领域的产品

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board |
| Lars Rebien Sorensen | Chair of Board |
| Maziar Mike Doustdar | President, CEO & Member of the Management Board |
| Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board |
| Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board |
| Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board |
| Cornelis de Jong | Independent Vice Chair of the Board |
| Stephan Engels | Independent Director |
| Desirée Jantzen Asgreen | Employee Representative Director |
| Mette Bojer Jensen | Employee Non-Independent Representative Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| Novo Holdings A/S | 28.23% | 2025-02-04 |
| BlackRock, Inc. | 4.08% | 2025-12-31 |
| The Vanguard Group, Inc. | 3.27% | 2026-02-28 |
| Norges Bank Investment Management | 1.61% | 2025-12-31 |
| Amundi Asset Management SAS | 0.62% | 2025-12-31 |
| Geode Capital Management, LLC | 0.60% | 2026-03-31 |
| State Street Global Advisors, Inc. | 0.41% | 2026-03-31 |
| JP Morgan Asset Management | 0.41% | 2026-03-31 |
| Loomis Sayles & Company, L.P. | 0.40% | 2026-01-31 |
| Deutsche Asset & Wealth Management | 0.40% | 2026-01-31 |

## 业务构成

| 业务线 | 营收 | 占比 |
|---------|---------|-------|
| 糖尿病和肥胖护理 | 289456000000 | 93.66% |
| 罕见病 | 19608000000 | 6.34% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Novo Nordisk A/S Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "糖尿病和肥胖护理",
        "ratio": 93.66
      },
      {
        "segment": "罕见病",
        "ratio": 6.34
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地区分布

| 地区 | 营收 | 占比 |
|--------|---------|-------|
| 美国 | 173166000000 | 56.03% |
| 欧洲和加拿大 | 66091000000 | 21.38% |
| 新兴市场 | 30436000000 | 9.85% |
| 亚太 | 20713000000 | 6.7% |
| Region China | 18658000000 | 6.04% |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**